Stock Analysis | Verisk Analytics Outlook - A Weak Technical Picture Amid Mixed Market Signals

Market Snapshot

Takeaway: Verisk Analytics (VRSK) shows a weak technical outlook with no bullish indicators and four bearish signals, suggesting investors should approach with caution. Meanwhile, the stock has seen positive fund flows across all investor sizes in recent days.

News Highlights

Recent news affecting VRSK includes:

• May 30, 2025: A new antitrust class action was filed against the UFC on behalf of non-UFC professional MMA fighters. While not directly linked to VRSK, it highlights growing legal scrutiny across industries, potentially impacting market sentiment.
• May 30, 2025: Major League Baseball announced a strategic investment in a new professional women's softball league. This could influence broader market trends in sports-related industries, which may have indirect effects on insurance and risk analytics firms like Verisk.
• May 28, 2025: The FDA approved DexCom's G4 Platinum Professional Continuous Glucose Monitoring system, a development in the healthcare tech space. While unrelated to Verisk's core offerings, it reflects broader technological advancements in health monitoring that could influence regulatory or industry dynamics in related sectors.

Analyst Views & Fundamentals

Analyst sentiment for VRSK is mixed. The simple average rating is 4.00, while the weighted rating is 0.00 due to poor historical performance by the sole recent analyst, Scott Wurtzel of Wolfe Research, who gave a "Buy" rating on September 3, 2025. This suggests a lack of consensus and caution in expectations.

Verisk’s fundamentals, according to internal diagnostic scores (0-10), show a weak profile, with an overall internal diagnostic score of 1.72. Key values and their scores include:

• Total operating revenue (YoY growth rate %): 7.38% (score: 1.72)
• Equity ratio (Total liabilities / Shareholders’ equity %): 14.38% (score: 1.72)
• Current assets turnover ratio: 1.33 (score: 1.72)
• Cash-MV: -1.26 (score: 1.72)
• Equity multiplier: 15.38 (score: 1.72)

These mixed fundamentals suggest a company under pressure, with weak profitability and liquidity indicators.

Money-Flow Trends

Big-money investors and institutional flows are showing positive signals. The fund-flow score for VRSK is 7.63 (good), indicating strong inflows across all investor sizes:

• Large and Extra-large investors: 50.05% and 53.02% inflow ratios, respectively
• Small and Medium investors: 50.36% and 50.57% inflow ratios, respectively

This positive fund flow is a counterbalance to the weak technical signals and suggests some market confidence in the near-term.

Key Technical Signals

Verisk Analytics shows a very bearish technical outlook. With zero bullish and four bearish indicators, the technical score is 2.6, one of the lowest possible. Key signals:

• WR Overbought: Internal diagnostic score of 2.26, a neutral rise, but with a negative historical average return of -0.37%
• WR Oversold: Internal diagnostic score of 3.24, a neutral rise, but with mixed win rate (50.98%)
• Bearish Engulfing: Internal diagnostic score of 1, a bearish signal with poor historical performance (28.57% win rate)
• MACD Golden Cross: Internal diagnostic score of 2.17, a neutral bias
• RSI Oversold: Internal diagnostic score of 4.31, but with a 54.55% win rate and 0.00% average return

In the last five days, recent patterns have included a Bearish Engulfing (9/2), WR Oversold (9/2, 8/28), and a MACD Golden Cross (8/18), all reinforcing the bearish tilt.

Conclusion

Verisk Analytics faces a challenging technical environment with no bullish indicators and a weak internal diagnostic score of 2.6. While fundamentals remain mixed and analyst ratings inconsistent, positive fund flows suggest some short-term investor interest.

Actionable takeaway: Given the weak technical signals and mixed fundamentals, it may be prudent to wait for a clearer trend or earnings catalyst before committing capital. Investors should monitor the stock for potential volatility and avoid overexposure in the near term.